Therefore, it may be speculated that sodium channel blockers, particularly Nav1.6 and Nav1.7 α subunit-specific blockers, have the potential to participate in the prevention and treatment of prostate cancer. This evidence concerns the gene SCN8A and prostate carcinoma.